263 related articles for article (PubMed ID: 19856885)
1. [Therapeutic intervention in diseases with advanced glycation end products in their pathogenesis].
Zuwała-Jagiełło J
Pol Merkur Lekarski; 2009 Aug; 27(158):152-6. PubMed ID: 19856885
[TBL] [Abstract][Full Text] [Related]
2. Advanced glycation end product (age) inhibitors and their therapeutic implications in diseases.
Takeuchi M; Yamagishi S; Iwaki M; Nakamura K; Imaizumi T
Int J Clin Pharmacol Res; 2004; 24(2-3):95-101. PubMed ID: 15689055
[TBL] [Abstract][Full Text] [Related]
3. Naturally occurring inhibitors against the formation of advanced glycation end-products.
Peng X; Ma J; Chen F; Wang M
Food Funct; 2011 Jun; 2(6):289-301. PubMed ID: 21779567
[TBL] [Abstract][Full Text] [Related]
4. Potential clinical utility of advanced glycation end product cross-link breakers in age- and diabetes-associated disorders.
Yamagishi S
Rejuvenation Res; 2012 Dec; 15(6):564-72. PubMed ID: 22950433
[TBL] [Abstract][Full Text] [Related]
5. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
Yamagishi S; Matsui T; Nakamura K
Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
[TBL] [Abstract][Full Text] [Related]
6. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes.
Yamagishi S; Maeda S; Matsui T; Ueda S; Fukami K; Okuda S
Biochim Biophys Acta; 2012 May; 1820(5):663-71. PubMed ID: 21440603
[TBL] [Abstract][Full Text] [Related]
7. Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease.
Yamagishi S; Nakamura K; Matsui T
Pharmacol Res; 2009 Sep; 60(3):174-8. PubMed ID: 19646657
[TBL] [Abstract][Full Text] [Related]
8. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.
Yamagishi S
Exp Gerontol; 2011 Apr; 46(4):217-24. PubMed ID: 21111800
[TBL] [Abstract][Full Text] [Related]
9. Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging.
Yan SF; D'Agati V; Schmidt AM; Ramasamy R
Curr Mol Med; 2007 Dec; 7(8):699-710. PubMed ID: 18331228
[TBL] [Abstract][Full Text] [Related]
10. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Matsui T; Inoue H; Takeuchi M
Med Hypotheses; 2007; 69(3):666-8. PubMed ID: 17331665
[TBL] [Abstract][Full Text] [Related]
11. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders.
Yamagishi S; Ueda S; Okuda S
Curr Pharm Des; 2007; 13(27):2832-6. PubMed ID: 17897026
[TBL] [Abstract][Full Text] [Related]
12. Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients.
Yamagishi S; Nakamura K; Inoue H
Med Hypotheses; 2005; 65(6):1013-5. PubMed ID: 16146671
[TBL] [Abstract][Full Text] [Related]
13. Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy.
Yamagishi S; Nakamura K; Matsui T
Curr Drug Discov Technol; 2006 Mar; 3(1):83-8. PubMed ID: 16712466
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease.
Yamagishi S; Fukami K; Matsui T
Int J Cardiol; 2015 Apr; 185():263-8. PubMed ID: 25814214
[TBL] [Abstract][Full Text] [Related]
15. Pathologic role of dietary advanced glycation end products in cardiometabolic disorders, and therapeutic intervention.
Yamagishi S; Matsui T
Nutrition; 2016 Feb; 32(2):157-65. PubMed ID: 26602289
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potentials of unicellular green alga Chlorella in advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Inoue H
Med Hypotheses; 2005; 65(5):953-5. PubMed ID: 15996828
[TBL] [Abstract][Full Text] [Related]
17. Substituted benzenediol Schiff bases as promising new anti-glycation agents.
Choudhary MI; Abbas G; Ali S; Shuja S; Khalid N; Khan KM; Atta-ur-Rahman ; Basha FZ
J Enzyme Inhib Med Chem; 2011 Feb; 26(1):98-103. PubMed ID: 20583858
[TBL] [Abstract][Full Text] [Related]
18. Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients.
Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M
Med Hypotheses; 2005; 64(6):1208-10. PubMed ID: 15823719
[TBL] [Abstract][Full Text] [Related]
19. Advanced glycation end products (AGEs) and their involvement in liver disease.
Hyogo H; Yamagishi S
Curr Pharm Des; 2008; 14(10):969-72. PubMed ID: 18473847
[TBL] [Abstract][Full Text] [Related]
20. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.
Srikanth V; Maczurek A; Phan T; Steele M; Westcott B; Juskiw D; Münch G
Neurobiol Aging; 2011 May; 32(5):763-77. PubMed ID: 19464758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
